Skip to main content

Table 1 Baseline demographics and clinical characteristics of patients a

From: Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial

Demographics and characteristics Data
Demographics and anthropomorphic measures
 Age (years) 51.0 (±14.2)
 Females (%) 82.4% (28)
 Race, Caucasians (%) 85.3% (29)
 Weight (kg) 77.3 (±18.1)
 BMI (kg/m2) 28.28 (±6.04)
Disease-related and laboratory indices
 DAS28-CRP (units) 4.58 (±1.10)
 Tender joints (n) 9.68 (±6.96)
 Swollen joints (n) 8.38 (±4.66)
 VAS (mm) 43.0 (±28.5)
 CRP (mg/dl) 12.69 (±24.57)
 ESR (mm/h) 22.8 (±21.3)
 HOMA (units) 3.11 (±2.68)
Current medication use
 Methotrexate (%) 70.6% (24)
 Leflunomide (%) 14.7% (5)
 Sulfasalazine (%) 2.9% (1)
 Hydroxycholorquine (%) 17.6% (6)
 Biologic (%) 52.9% (18)
 Corticosteroid (%) 52.9% (18)
  1. aData are presented as mean (±SD) for continuous data and percentage (number) for categorical variables. BMI, body mass index; CRP, high-sensitivity C-reactive protein; DAS28-CRP, Disease Activity Score in 28 joints high-sensitivity C-reactive protein; ESR, erythrocyte sedimentation rate; HOMA, homeostatic model assessment of insulin resistance; VAS, Visual Analogue Scale for Global Health.